First Tracks Biotherapeutics Inc(TRAX)

$44.19—

Chart

First Tracks Biotherapeutics Inc(TRAX)

NASDAQ

$44.19—

Chart Studio

TRAX(TRAX)

TRAX

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

No analyst ratings available

Price Target Expectations

Bear

$46.00

+4.1%

Consensus

$60.00

+35.8%

Bull

$95.00

+115.0%

12-Month Target Range0 analysts

$46.00$60.00$95.00

Current $44.19Consensus

Current Price

$44.19

Upside to Consensus

$15.81

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev—

EPS—

FY2028

Rev—

EPS—

FY2029

Rev—

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$75M	—	—	$42M	$47M
Low	$75M	—	—	$42M	$47M
High	$75M	—	—	$42M	$47M
EBITDA Avg	—	—	—	—	—
Low	—	—	—	—	—
High	—	—	—	—	—
EBIT Avg	—	—	—	—	—
Low	—	—	—	—	—
High	—	—	—	—	—
Net Income Avg	$-147M	$-150M	$-135M	$-128M	$-141M
Low	$-149M	$-157M	$-162M	$-128M	$-141M
High	$-136M	$-101M	$-108M	$-128M	$-141M
EPS Avg	$-4.06	$-3.66	$-3.93	$-3.68	$-4.06
Low	$-4.28	$-4.50	$-4.66	$-3.68	$-4.06
High	$-3.92	$-2.91	$-3.09	$-3.68	$-4.06
Analysts (Rev / EPS)	4 / 6	— / 6	— / 6	4 / 3	3 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	—	—	—	—	—	—
Low	—	—	—	—	—	—
High	—	—	—	—	—	—
EBITDA Avg	—	—	—	—	—	—
Low	—	—	—	—	—	—
High	—	—	—	—	—	—
EBIT Avg	—	—	—	—	—	—
Low	—	—	—	—	—	—
High	—	—	—	—	—	—
Net Income Avg	$-31M	$-29M	$-29M	$-28M	$-29M	$-29M
Low	$-33M	$-32M	$-29M	$-28M	$-29M	$-29M
High	$-27M	$-25M	$-29M	$-28M	$-29M	$-29M
EPS Avg	$-0.88	$-0.83	$-0.81	$-0.78	$-0.81	$-0.82
Low	$-0.93	$-0.90	$-0.81	$-0.78	$-0.81	$-0.82
High	$-0.77	$-0.70	$-0.81	$-0.78	$-0.81	$-0.82
Analysts (Rev / EPS)	— / 6	— / 6	— / 2	— / 2	— / 2	— / 2

Earnings Surprises

Recent Analyst Actions

Aug 13, 2026Piper Sandler

First Tracks Biotherapeutics price target raised to $95 from $54 at Piper Sandler

Target:$95.00

+105.9%from $46.13

Aug 13, 2026H.C. Wainwright

First Tracks price target raised to $57 from $44 at H.C. Wainwright

Target:$57.00

+23.6%from $46.13

Aug 13, 2026Barclays

First Tracks Biotherapeutics price target raised to $65 from $48 at Barclays

Target:$65.00

+40.9%from $46.13

Aug 10, 2026UBS

First Tracks Biotherapeutics price target raised to $65 from $45 at UBS

Target:$65.00

+38.8%from $46.83

Jul 28, 2026Wedbush

First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush

Target:$60.00

+43.1%from $41.92

Jul 28, 2026Wells Fargo

First Tracks Biotherapeutics price target raised to $55 from $30 at Wells Fargo

Target:$55.00

+30.9%from $42.03

Jul 21, 2026Barclays

First Tracks Biotherapeutics price target raised to $48 from $40 at Barclays

Target:$48.00

+30.2%from $36.87

Jul 10, 2026H.C. Wainwright

First Tracks Biotherapeutics price target raised to $44 from $30 at H.C. Wainwright

Target:$44.00

+35.8%from $32.40

Jun 8, 2026Wells Fargo

First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo

Target:$30.00

+80.7%from $16.60

May 4, 2026Piper Sandler

First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler

Target:$54.00

+141.3%from $22.38

Apr 28, 2026H.C. Wainwright

First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright

Target:$30.00

+65.7%from $18.10

Apr 24, 2026Leerink Partners

First Tracks Biotherapeutics initiated with an Outperform at Leerink

Target:$46.00

+142.1%from $19.00

Apr 21, 2026UBS

First Tracks Biotherapeutics initiated with a Buy at UBS

Target:$45.00

+141.9%from $18.60

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance